258 related articles for article (PubMed ID: 35158866)
1. PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers.
Collet L; Péron J; Penault-Llorca F; Pujol P; Lopez J; Freyer G; You B
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158866
[TBL] [Abstract][Full Text] [Related]
2. Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
Dawood S; Konstantinova M; Perazzo F; Kim SB; Villarreal-Garza C; Franco SX; Simon SD; El-Nahas T
Chin Clin Oncol; 2020 Oct; 9(5):61. PubMed ID: 32819114
[TBL] [Abstract][Full Text] [Related]
3. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
4. Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status.
Keung MY; Wu Y; Badar F; Vadgama JV
J Clin Med; 2020 Mar; 9(4):. PubMed ID: 32235451
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
Zhang M; Yu X; Wang J; Li Y; Cao L
J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) polymerase inhibitors in the treatment landscape of triple-negative breast cancer (TNBC).
El Gazzar WB; Albakri KA; Hasan H; Badr AM; Farag AA; Saleh OM
J Oncol Pharm Pract; 2023 Sep; 29(6):1467-1479. PubMed ID: 37559370
[TBL] [Abstract][Full Text] [Related]
7.
Petracci FE; Villarreal-Garza C; Argañaraz F; Abuin GG; Peñaloza J; Flores MA; Piazzoni L; Riggi C; Fabiano L; González L; Cieplinski B; Rivero S; Korbenfeld E; Mandó P
Ecancermedicalscience; 2023; 17():1634. PubMed ID: 38414929
[TBL] [Abstract][Full Text] [Related]
8. PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology.
Miglietta F; Cinquini M; Dieci MV; Cortesi L; Criscitiello C; Montemurro F; Del Mastro L; Zambelli A; Biganzoli L; Levaggi A; Delle Piane C; Marchiò C; Calabrese M; Fortunato L; Franco P; Meduri B; Fittipaldo VA; Gori S
Breast; 2022 Dec; 66():293-304. PubMed ID: 36379199
[TBL] [Abstract][Full Text] [Related]
9. Single-agent PARP inhibitors for the treatment of patients with
Poggio F; Bruzzone M; Ceppi M; Conte B; Martel S; Maurer C; Tagliamento M; Viglietti G; Del Mastro L; de Azambuja E; Lambertini M
ESMO Open; 2018; 3(4):e000361. PubMed ID: 29942664
[TBL] [Abstract][Full Text] [Related]
10. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
Pop L; Suciu I; Ionescu O; Bacalbasa N; Ionescu P
J Med Life; 2021; 14(1):17-20. PubMed ID: 33767780
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
Wang X; Shi Y; Huang D; Guan X
Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
[TBL] [Abstract][Full Text] [Related]
12. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
13. Breast Cancer and Genetic
Lux MP; Fasching PA
Geburtshilfe Frauenheilkd; 2023 Mar; 83(3):310-320. PubMed ID: 36908286
[TBL] [Abstract][Full Text] [Related]
14. Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
Ballot E; Galland L; Mananet H; Boidot R; Arnould L; Desmoulins I; Mayeur D; Kaderbhai C; Ilie S; Hennequin A; Bergeron A; Derangère V; Ghiringhelli F; Truntzer C; Ladoire S
Breast Cancer Res; 2022 Nov; 24(1):80. PubMed ID: 36401316
[TBL] [Abstract][Full Text] [Related]
15. Management of human epidermal growth factor receptor 2-negative metastatic breast cancer: Role of poly adenosine diphosphate (ADP-ribose) polymerase inhibitors.
Vaid AK; Deshmukh C; Rohatgi N; Ghosh J
Indian J Cancer; 2022 Mar; 59(Supplement):S130-S141. PubMed ID: 35343197
[TBL] [Abstract][Full Text] [Related]
16. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
17. Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.
Mahtani R; Niyazov A; Arondekar B; Lewis K; Rider A; Massey L; Lux MP
BMC Cancer; 2022 Dec; 22(1):1343. PubMed ID: 36550413
[TBL] [Abstract][Full Text] [Related]
18. Real-world data in patients with
Beas-Lozano EL; Verduzco-Aguirre HC; Gonzalez-Salazar R; Chavarri-Guerra Y
Ecancermedicalscience; 2023; 17():1633. PubMed ID: 38414963
[TBL] [Abstract][Full Text] [Related]
19. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
[TBL] [Abstract][Full Text] [Related]
20. PARP Inhibitors for Breast Cancer: Germline
Menezes MCS; Raheem F; Mina L; Ernst B; Batalini F
Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]